Following on from information provided to NICE by the company in June 2021, the appraisal of Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1514 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in June 2021, the appraisal of Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2021, the appraisal of Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 August 2021 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 19 September 2019 | In progress. In progress |
| 19 September 2019 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. |
| 14 January 2019 (10:00) | Scoping workshop (Manchester) |
| 16 November 2018 - 14 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual